Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the Effect of Different Treatments on Pain Scores and Self-reported Oral Health-related Quality of Life in Individuals With Burning Mouth Syndrome
NCT06040190Phase 4Completed
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of clonazepam, alpha-lipoic acid, capsaicin 8% patch in burning mouth syndrome (BMS), sponsored by Universidade Federal de Minas Gerais. Started Nov 2023; status: completed.
02
Drugs
clonazepamalpha-lipoic acidcapsaicin 8% patch
03
Conditions
burning mouth syndrome (BMS)
Beyond the preview
Go deeper on NCT06040190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040190.